Community Practice Connections™: Sickle Cell Disease: Targeting Complications to Improve Long-term Implications
February 25, 2021
February 25, 2022
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
- Physicians — maximum of 1.50 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
These activities are intended for medical hematologists and other health care professionals (HCPs) interested in the latest advances in the treatment of patients with SCD, including pediatricians and emergency medicine physicians. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other HCPs interested in the treatment of patients with hematologic diseases will also be invited to attend.
Painful vaso-occlusive crisis is the hallmark clinical feature of sickle cell disease (SCD) and it greatly impacts morbidity and mortality. As such, there has been a call to action to develop treatments to address this disease manifestation and its underlying causes. That call is being answered in the form of novel therapies introduced in recent years, with commensurate updates to best practices and treatment guidelines. It is vital that clinicians receive timely and relevant education that helps them optimize care of their patients with SCD.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the live virtual symposium held on December 4, 2020. This unique and engaging multimedia activity is ideal for the community-based clinician because it focuses on patient-centric strategies for managing SCD that are practical, guideline-congruent, and implementation-ready. The activity also shares data about ongoing therapeutic advances on the horizon that offer renewed hope for enhanced management and potentially cure of SCD.
Upon completion of this activity, you should be better prepared to:
- Summarize diagnostic criteria and management guidelines in the evaluation and treatment of SCD
- Explain efficacy and safety data supporting novel therapeutic modalities in SCD
- Develop strategies to integrate multidisciplinary care into treatment selection and decision-making in SCD
- Identify common and uncommon treatment complications to improve patient outcomes during treatment
Kenneth I. Ataga, MD
Professor of Medicine and Pediatrics
Methodist Endowed Chair in Sickle Cell Anemia
Director, Center for Sickle Cell Disease
University of Tennessee Health Science Center
Julie Kanter, MD
Associate Professor of Medicine
Co-Director of the Comprehensive Sickle Cell Center
The University of Alabama at Birmingham
Abdullah Kutlar, MD
Professor of Medicine
Dr William N. Agostas and Josephine R. Agostas Chair in Internal Medicine
Division of Hematology/Oncology & Stem Cell Transplantation
Director, Center for Blood Disorders
Medical College of Georgia
Bernard L. Lopez, MD, MS, CPE, FACEP, FAAEM
Associate Provost for Diversity and Inclusion
Associate Dean for Diversity and Community Engagement
Professor and Executive Vice Chair, Department of Emergency Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Kenneth I. Ataga, MD
- Grant Research Support: Novartis, Shire/Takeda
- Consultant: Agios Pharmaceuticals, Editas Medicine, Form Therapeutics Global Blood Therapeutics, Novartis, Roche
Julie Kanter, MD
- Grant Research Support: National Heart, Lung, and Blood Institute, Centers for Disease Control and Prevention, Health Resources and Services Administration
- Consultant: Agios Pharmaceuticals, Beam Therapeutics , Forma Therapeutics, GLG, Guidepoint Global, Novartis, Sanofi
Abdullah Kutlar, MD has no relevant financial relationships with commercial interests to disclose.
Bernard L. Lopez, MD, MS, CPE, FACEP, FAAEM has no relevant financial relationships with commercial interests to disclose.
The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.